<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal CancerJeremy Jones, Axel Grothey, Lindsay A. Renfro et al.|Journal of Clinical Oncology|2017Cited by 357
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Takayuki Yoshino et al.|The Lancet|2023Cited by 319